June 26, 2026

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.

Conexiant

June 26, 2026

FDA Monthly Preview: Key July Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Conexiant

June 26, 2026

Is Accelerated Aging Tied to Early-Onset Carcinogenesis?

Researchers found larger biological age gaps in more recent birth cohorts and observed associations with higher risk of several cancers diagnosed before age 55.

Conexiant

June 26, 2026

Surveillance May Reduce CIN 2 Overtreatment

Risk-based management may reduce unnecessary excisions in selected patients with CIN 2.

Conexiant

June 23, 2026

When Should Breast Cancer Risk Scores Trigger MRI?

A JAMA Internal Medicine Viewpoint urges clinicians and health systems to verify risk-model inputs before acting on automated breast cancer screening recommendations.

Conexiant

June 15, 2026

Dana-Farber Research News 06.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from May 16 - 31.

Dana-Farber

June 11, 2026

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Conexiant

June 04, 2026

NHS-Galleri Linked to Delays

Analysis of England’s multicancer early detection screening trial found modest, temporary diagnostic delays in participating regions, adding to concerns about health system effects and the evidence base for population-level blood-based cancer screening.

Conexiant

June 02, 2026

ADC Provides Patients with Better Results Even After Subsequent Therapy for Advanced Triple-Negative Breast Cancer

A shift in the way advanced triple-negative breast cancer is treated may be on the horizon with mounting evidence that moving sacituzumab govitecan, an antibody-drug conjugate (ADC), to the first line of treatment confers long-term benefit compared to standard therapy, including continued benefit even after subsequent therapy.

Dana-Farber

June 02, 2026

Comprehensive Cancer Care for the Doral Community

Baptist Health Cancer Care is now serving patients in Doral with a comprehensive, community-based approach to oncology care designed to make treatment more convenient and accessible for both patients and referring physicians.

Baptist Health South Florida